Lensar (LNSR) Net Income towards Common Stockholders Growth (1y) (2020 - 2026)
Lensar (LNSR) Net Income towards Common Stockholders Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 121.14% |
| 10 | Lensar | 65.43 Mn | 54.33 Mn | 6.38 Mn | 169.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169.17% |
| Dec 31, 2025 | 92.20% |
| Sep 30, 2025 | -147.20% |
| Jun 30, 2025 | 80.49% |
| Mar 31, 2025 | -1,167.73% |
| Dec 31, 2024 | -376.36% |
| Sep 30, 2024 | -204.82% |
| Jun 30, 2024 | -3.31% |
| Mar 31, 2024 | 49.51% |
| Dec 31, 2023 | -57.67% |
| Sep 30, 2023 | 135.91% |
| Jun 30, 2023 | -29.50% |
| Mar 31, 2023 | 35.99% |
| Dec 31, 2022 | 36.19% |
| Sep 30, 2022 | 35.16% |
| Jun 30, 2022 | -54.95% |
| Mar 31, 2022 | -28.79% |
| Dec 31, 2021 | 42.85% |
| Sep 30, 2021 | -29.23% |
| Jun 30, 2021 | 3.00% |